Programs

To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

Bespoke Gene Therapy Consortium (BGTC)

The Bespoke Gene Therapy Consortium (BGTC) is a developing public-private partnership dedicated to making gene therapy a reality for people with rare genetic diseases affecting populations too small to be viable from the current commercial perspective. Building on the successful Accelerating Medicines Partnership model, this program will focus on developing an operational playbook that invokes the use of streamlined templates, master regulatory files, and uniform production processes. It is anticipated that following a pilot phase of 4-6 test cases, a pathway toward the commercial viability of these therapies will be found. This may ultimately have a tremendously positive impact on the larger field of gene therapy if it moves more broadly into the era of genome editing.

Fogarty International Center's 50th Anniversary

The National Institutes of Health (NIH)’s Fogarty International Center celebrated its 50th anniversary of accomplishments and hosted a Scientific Symposium on May 1st, 2018 at the Natcher Auditorium on NIH’s campus. The program convened a series of panel discussions with NIH leaders, Fogarty grantees, and key stakeholders, to identify key gaps in global health research and strategize future research initiatives.

International Summit in Human Genetics and Genomics

The International Summit in Human Genetics and Genomics is a five-year initiative (2016-2020) designed to help developing nations build and expand their knowledge base, infrastructure, systems and technologies in genetics and genomics. Each fall, researchers from abroad travel to the National Institutes of Health in Bethesda, Maryland for one month of in-person training at the National Human Genome Research Institute (NHGRI). The Summit helps them to understand the prevalence and basis of genetic diseases in their nations and to address these public health challenges. The 2020 Summit will be held on August 31 - October 1, 2020.

Dr. Edward T. Rancic Memorial Fund for Cancer Research

The Dr. Edward T. Rancic Memorial Fund for Cancer Research supports a Fellow in the laboratory of Dr. Richard Childs at the National Heart, Lung, and Blood Institute (NHLBI) to explore treatments for renal cell carcinoma.

Dean R. O'Neill Renal Cell Cancer Research Fund

The Dean R. O'Neill Renal Cell Cancer Research Fund supports a Fellow in the laboratory of Dr. Richard Childs at the National Heart, Lung, and Blood Institute (NHLBI) to explore treatments for renal cell carcinoma.

Clayton-Dedonder Mentorship Fellows Program

Clayton-Dedonder Mentorship Fellows Program is designed to enhance the teaching and leadership skills of entry- to mid-level faculty at universities and research institutions in low- and middle-income countries at select training sites funded by the NIH Fogarty International Center.

Heart Truth Community Action Program Grants

The Heart Truth® is a national awareness campaign for women about heart disease, sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. Heart disease is the leading cause of death for American women. Yet many women still do not take heart disease seriously or personally.

Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development (MAL-ED)

The study was implemented using shared and harmonized protocols across the eight sites to gather an enormous amount of data (physical, cognitive assessments, diet, illness and enteric infection, socio-economic status, etc.) to enable identification and characterization of factors associated with negative impacts on a child’s growth, development and vaccine response early in life.

Biomarkers Consortium - The Performance of Novel Cardiac Biomarkers in the General U.S. Population

The Biomarkers Consortium’s Novel Cardiac Biomarkers in the General US Population (the Cardiac Troponin Project) seeks to define the reference ranges and to generate the epidemiologic basis for the use of several significant novel cardiac and related biomarkers for cardiovascular risk stratification in the general U.S. population. The program will measure a panel of biomarkers in almost 30,000 individuals in a national study. The project will provide key reference data regarding novel biomarkers for cardiovascular risk stratification and inform U.S. clinical and laboratory guidelines.

Biomarkers Consortium - Carotid MRI Development and Validation via an AIMHIGH Sub-Study

The goal of this project was to conduct a 75-patient study at a total of 15 centers to determine the reproducibility of the non-invasive technique of carotid magnetic resonance imaging (CMRI). Results established a standardized carotid MRI protocol and determined, for the first time, that kinetic parameters of carotid atherosclerotic plaque are reproducible and can be used for multi-center studies.